Intensity Therapeutics, Inc.
INTS Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$3.25
KIRA · Stoqly’s AI analyst, in plain words
- Intensity Therapeutics, Inc. lost $11.6M in fiscal 2025.
Market cap
$8.8M
P/E
—
Revenue
—
Net income
−$11.6M
Free cash flow
—
Operating margin
—
Intensity Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$11.6M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Intensity Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Legal name
- INTENSITY THERAPEUTICS, INC.
- CIK
- 0001567264
Intensity Therapeutics, Inc. · INTS
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Net income | −$7.6M | −$10.5M | −$16.3M | −$11.6M |
| Diluted EPS | −$2.22 | −$1.38 | −$29.24 | −$8.56 |
| Cash | ||||
| Cash from operations | −$5.5M | −$7.2M | −$15.2M | −$9.2M |
| Share count change | — | 152.7% | −93.5% | 143.8% |
| Debt and strength | ||||
| Cash and short-term investments | $1.3M | $8.6M | $2.6M | $11.9M |
| Shareholders' equity | −$15.1M | $13.2M | $2.9M | $11.9M |
| Current ratio | 0.2x | 3.9x | 1.9x | 5.9x |
| Interest coverage | −92.1x | −27.3x | — | — |
| Returns and quality | ||||
| Return on equity | — | — | −202.3% | −156.9% |
| Return on tangible equity | — | −80.1% | −557.5% | −97.7% |
| Altman Z'' | −122.9 | −5.0 | −65.0 | −13.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Intensity Therapeutics, Inc. · INTS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.25 a share, the company is worth $8.8M.
Source: SEC EDGAR XBRL filings (CIK 0001567264). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.